secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001140361-25-039463
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Phase 3 FORTIFY study hits all primary and secondary endpoints for BBP-418 in LGMD2I/R9
--------------------------------------------------------------------------------

- Primary endpoint: glycosylated αDG increased 1.8x from baseline at 3 months (p<0.0001); sustained at 12 months.
- Serum CK (muscle damage marker) reduced by 82% from baseline vs placebo at 12 months (p<0.0001).
- 100-meter walk test velocity improved 0.27 m/s vs placebo at 12 months (p<0.0001).
- FVC pulmonary function improved ~5% predicted volume vs placebo at 12 months (p=0.0071).
- Company plans to file NDA with FDA in first half 2026; safety profile consistent with prior studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036125039463/0001140361-25-039463-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036125039463/ef20057750_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-039463

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer